Get the Stockscreener App
16.79
3.12%
-0.54
After Hours:
16.79
Eton Pharmaceuticals Inc stock is traded at $16.79, with a volume of 167.31K.
It is down -3.12% in the last 24 hours and up +32.73% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$17.33
Open:
$17.47
24h Volume:
167.31K
Relative Volume:
0.69
Market Cap:
$465.02M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-64.58
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
-3.17%
1M Performance:
+32.73%
6M Performance:
+91.23%
1Y Performance:
+388.79%
1-Day Range:
$16.77
$17.74
1-Week Range:
$16.43
$17.74
52-Week Range:
$3.18
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
16.79 | 465.02M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Envestnet Asset Management Inc. Invests $236,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33% - simplywall.st
Eton Pharmaceuticals Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - The Manila Times
Eton Pharmaceuticals to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Rare Disease Leader Eton Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Q1 EPS Estimate for Eton Pharmaceuticals Boosted by Analyst - Defense World
JPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
B. Riley Raises Earnings Estimates for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
Eton Pharmaceuticals (ETON) Submits NDA for New Treatment for Ce - GuruFocus
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment (ETON:NASDAQ) - Seeking Alpha
Eton Pharmaceuticals Submits NDA to FDA for ET-600 to Treat Central Diabetes Insipidus - marketscreener.com
Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch - marketscreener.com
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - GlobeNewswire
Groundbreaking Pediatric Diabetes Drug Advances: First-Ever Liquid Formulation Heads to FDA Review - Stock Titan
Geode Capital Management LLC Sells 4,050 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance
Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com
Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st
(ETON) Technical Data - news.stocktradersdaily.com
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):